Lorlatinib/Lorlatinib (Lorlatinib) comes in several versions

Lorlatinib/Lorlatinib (lorlatinib) is an oral kinase inhibitor. It is a third-generation targeted drug with in vitro resistanceALK and ROS1 and TYK1, FER< span>、FPS、TRKA、TRKB、 Activities of TRKC, FAK, FAK2 and ACK. Lorlatinib has shown activity in vitro against multiple mutated forms of the ALK enzyme, including some detected in tumors undergoing disease progression with crizotinib and other ALK inhibitors.

Lorlatinib/Lorlatinib has been launched in China. Lorlatinib is an anti-cancer drug developed by Pfizer. In addition to the original research, there are currently many overseas manufacturers producing lorlatinib. Different manufacturers have different specifications and costs. The retail price of Everest pharmaceutical manufacturers in Bangladesh100mg30tablets5000yuan, the retail price of pharmaceutical manufacturers in Laos and ASEAN100mg30tablets3The price of 100 mg 30 tablets of Laos Element Pharmaceuticals is around 1,078, and the retail price of Laos United Pharmaceuticals is 3about 1,078. Patients can choose drugs according to their own conditions.

The cost of the original research of lorlatinib is relatively high, which is a relatively high cost for most patients and puts great financial pressure. Patients can choose the overseas version of the drug according to their own financial situation. The drug ingredients and specifications are the same and the effects are similar. The most common lorlatinib(incidence ≥20%)adverse reactions and3-4Level laboratory abnormalities were edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.